---
aliases:
  - metformin
  - sulphonylureas
  - antidiabetic drugs
tags:
  - pharmacology
  - diabetes
urls:
  - https://youtu.be/4Y7wdX7iEAY
---
# Mechanism of action
![MoA](https://youtu.be/4Y7wdX7iEAY)
*See [[diabetes treatment]].* 
## Insulin Sensitisers
Metformin also reduces hepatic gluconeogenesis

| Class                                   | Medication   | Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| --------------------------------------- | ------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Biguanides                              | Metformin    | Reduces weight and is 1st drug for DM type 2. It is weight neutral so patient weight doesn't matter. Associated with B12 deficiency in some patients. <br><br>Max dose is 2g/day.<br><br>**S/E**<br>c/i in CKD<br>- Reduce dose if GFR <45.<br>- Stop dose if eGFR <30.<br><br>GI upset common: Can cause diarrhoea on starting.<br>- Titrate up slowly to reduce GI s/e.<br>- If too much s/e, switch to Modified release. <br>- If diarrhoea, stop/reduce DAMN: Diuretics, [[ace inhibitors\|ACE]]i, ARB, Metformin, NSAID. <br><br>(not to be confused with [[lithium\|DAMN drugs causing Li toxicity]]) #confusion <br><br>Lactic acidosis<br>- Stop in tissue hypoxia conditions:<br>- MI: Give DIGAMI (Diabetes Mellitus, Insulin–Glucose Infusion in Acute Myocardial Infarction) regimen. #mnemonic <br>- Sepsis<br>- AKI<br>- Severe dehydration |
| Glitazones /<br>Thiazolidinedione (TZD) | Pioglitazone | Not commonly used in UK, but licensed. <br><br>Increases weight.<br>**c/i** in Obese, HF, Bladder cancer, hepatic impairment<br>Increases risk of # in postmenopausal women.<br><br>Keep monitoring LFTs every 6months. Do FBC, LFT before starting rx.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
## Glucose independent insulin secretion

| Class              | Medication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Notes                                                                                               |
| ------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------- |
| **Sulphonylureas** | Glibenclamide, Gliclazide, Glipizide c/i in renal impairment as it increases the risk of hypoglycemia<br><br>Increases weight so c/i in obese.<br><br>Associated with hypoglycemia in fasted state, so don't give to patients needing to be alert/can't eat. Also  causes weight gain. <br><br>Since they work on beta cells, if the disease has been going on for a long time, there's no beta cells left so they'll stop having any effects on the patient. Only side effect. So it's not common in elderly people.  . |                                                                                                     |
| **Meglitinide**    | Repaglinide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Risk of hypoglycemia, weight gain  <br>Can cause DKA even at moderately raised blood sugar (<14mmol |
## Glucose dependent Insulin secretion

| Class                                | Medication                                                                                                                                                                                                                                                                                                                                            | Notes                                                                                                                                                                                                                                                       |
| ------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| DPP4 inhibitors (Incretin enhancers) | Gliptin<br><br>GIP & GLP-1 gets broken down 2 mins after its release. MoA: prevents GLP-1 breakdown. But doesn't give bonus effects of GLP-1 except the insulin release.                                                                                                                                                                              | c/I in Heart Failure & Pancreatitis.<br><br>Doesn’t affect weight.  <br>Can cause Euglycemic DKA especially if taken during illnesses that can cause dehydration.                                                                                           |
| GLP-1 agonist                        | Incretin mimetics: exenatide, dulaglutide (Trulicity), liraglutide, lixisenatide and semaglutide (Ozempic).<br>These are modified GLPs which can't be broken down by DPP-4. <br><br>GLP-1 is produced from ileum when there's more glucose and it stimulates pancreas to release insulin.<br>- Also causes reduced appetite & slows gastric emptying. | Too costly.  <br>Exenatide lowers weight but NICE says to use in >35kg/m2 BMI.<br><br>Reduces gastric motility so you feel full longer. <br><br>has weight loss benefits, CVS benefit, renal benefit, HFpEF, sleep apnoea, MASLD, Osteoarthritis, Dementia. |
## Glucose excretion
SGLT1 works in descending tubules and absorbs 10% glucose and SGLT2 in proximal tubule absorbs 90% of glucose. So when SGLT2 inhibits, it prevents Na:Glucose::1:1 reabsorption. 

| Class             | Medication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Notes |
| ----------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |
| SGLT-2 inhibitors Gliflozin<br>(empa, cana, dapa, ertu-gliflo Works on & inhibits reabsorption of glucose in renal tubules.<br><br>Reduces weight. <br>-> Indicated in risk of Heart Failure/CVD/Q-Risk > 10%<br><br>Contraindicated if GFR <60<br>can cause electrolyte disturbance<br><br>Euglycemia DKA if risk of dehydration when ill, so discuss: <br>-> Maintain adequate fluid intake.<br>-> [[Sick day rules]]<br>Fournier's gangrene<br>Can cause UTI due to excretion of glucose in urine. <br>- Fungal genital infections- thrush.  .  |       |
#### NICE criteria for SGLT-2 
If not high CVD risk: ([link to flowchart](https://www.nice.org.uk/guidance/ng28))
- SGLT2 can be monotherapy if Metformin not acceptable, & lifestyle changes didn't provide adequate glycaemic control. 
- The SGLT2 inhibitors are recommended only if a DPP-4 inhibitor (gliptin) would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. 

If CHF/established atherosclerotic CVD, then offer / if high CVD risk >10%, offer: 
- Start metformin alone to assess tolerability before adding an SGLT2 inhibitor
- Once you know tolerance to Metformin, start SGLT2 inhibitor (either alone or with metformin)

## Reduce dietary glucose absorption
Acarbose (alpha-1 glucosidase inhibitors). Not common in UK. Inhibits enzymes for digestion of carbs, so taken with meals. Leads to flatulence & diarrhoea. 

---
# Contraindications
#mnemonic 

| Condition                                | Drugs to avoid                                                                                                                   |
| ---------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------- |
| With bad kidneys (GFR < 30), avoid MS    | Metformin, Sulfonylurea                                                                                                          |
| Renal **safe** drugs                     | RIP: Repaglinide, Linagliptin, Pioglitazone                                                                                      |
| With obesity,<br><br>==avoid== P(q)RS    | Pioglitazones, Repaglinide, Sulfonylurea.<br><br>Rest cause weight loss.<br><br>Gliptins (DPP-4 inhibitors) don’t affect weight. |
| RS (no P) have high risk of hypoglycemia | Repaglinide, Sulfonylurea.                                                                                                       |
| Pancreatitis                             | avoid Gliptins (DDP-4 inhibitors)                                                                                                |
| Heart failure (4 chambers)               | avoid Gliptins (DDP-4 inhibitors)<br><br>also avoid Glitazones in HF as can cause  peripheral edema.                             |
| Pie = Die (bladder cancer)               | avoid Pioglitazone                                                                                                               |
